Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
AUSTIN, Texas, May 16, 2017 -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the UBS 2017 Global Healthcare Conference in New York on Tuesday, May 23 at 1:00 p.m. ET.
To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. The webcast and presentation will be archived for viewing for 90 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine.
For more information, please visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
